Moreover, PM/Scl antibodies were correlated with longer disease duration [OR 4.50 95% CI 1.39–14.6, p = 0.01], whereas anti-TIF1-γ was associated with a lower calcinosis prevalence in adult DM [OR 0.80, 95% CI 0.85–0.99, p = 0.03]. Here, TRIM33 is linked to dermatomyositis.